Structure of the human histamine H1 receptor complex with doxepin

By T. Shimamura, M. Shiroishi, S. Weyand, Hirokazu Tsujimoto, G. Winter, Vsevolod Katritch, Ruben Abagyan, Vadim Cherezov, Wei Liu, G. Han and 3 more. Nature, 2011

796 citations recorded by the source corpus.

The biogenic amine histamine is an important pharmacological mediator involved in pathophysiological processes such as allergies and inflammations. Histamine H1 receptor (H1R) antagonists are very effective drugs alleviating the symptoms of allergic reactions. Here we show the crystal structure of the H1R complex with doxepin, a first-generation H1R antagonist. Doxepin sits deep in the ligand-binding pocket and directly interacts with Trp 4286.48, a highly conserved key residue in G-protein-coupled-receptor activation. This well-conserved pocket with mostly hydrophobic nature contributes to the low selectivity of the first-generation compounds. The pocket is associated with an anion-binding region occupied by a phosphate ion. Docking of various second-generation H1R antagonists reveals that the unique carboxyl group present in this class of compounds interacts with Lys 1915.39 and/or Lys 179ECL2, both of which form part of the anion-binding region. This region is not conserved in other aminergic receptors, demonstrating how minor differences in receptors lead to pronounced selectivity differences with small molecules. Our study sheds light on the molecular basis of H1R antagonist specificity against H1R.

Subfields: Immunology, Immunology and Allergy, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/b2f040863057dd42b7c104a1c1d9fd12ccf197ef

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Structure-based drug screening for G-protein-coupled receptors. (2012, background): “Since the initial crystal structures of the β2AR[11] and the β1AR[12], the number of published GPCRs which have yielded to crystallography has grown to ten and includes the adenosine A2A receptor[13], the D3 dopamine receptor[14], the CXCR4 receptor [15], the histamine H1 receptor, [16], the sphingo”
GPCR Network: a large-scale collaboration on GPCR structure and function (2012, background): “23) , dopamine D 3 receptor 24 , histamine H 1 receptor 25 , S1PR1 (REF.”
The Protein Structure Initiative: achievements and visions for the future (2012, background): “Some important integral membrane protein structures, including several G protein-coupled receptors, known as GPCRs, and their complexes with ligands, have recently been determined in PSI-funded projects using both X-ray crystallography [62-71] andNMR spectroscopy [72,73].”
Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment (2011, positive): “GPCR Phylogenetic Tree Highlighting the Recently Solved GPCR Structures and Their Homologs Flags indicate high-resolution structures of b1 and b2 adrenergic (red), adenosine A2A receptor (yellow), dopamine D3 (cyan), histamine H1 (Shimamura et al., 2011) (orange), and chemokine CXCR4 (green) recepto”
Assessment and Challenges of Ligand Docking into Comparative Models of G-Protein Coupled Receptors (2013, neutral): “…receptors: rhodopsin [14], b 1-adrenergic [15], b 2-adrenergic [16], A2A adenosine [17], CXCR4 chemokine [18], dopamine D3 [19], histamine H1 [20], S1P1 sphingosine 1-phosphate [21], M2 muscarinc acetylcholine [22], M3 muscarinic acetylecholine [23], mu-opioid [24], kappa-opioid [25], N/OFQ…”
Loss of constitutive activity is correlated with increased thermostability of the human adenosine A2A receptor (2013, background): “Significant progress has been made through the development of GPCR fusion proteins, where a T4 lysozyme replaces the conformationally dynamic third intracellular loop (ICL3), for example (Cherezov et al., 2007; Jaakola et al., 2008; Chien et al., 2010; Wu et al., 2010; 2012; Shimamura et al., 2011; ”
A Structural Framework for GPCR Chemogenomics: What's In a Residue Number? (2018, neutral): “3 Bulges and constrictions in GPCR crystal structures determining the structure of ligand binding sites: H1 (PDB: 3RZE [25]), CXCR4 (PDB: 3ODU [26]), β1 (PDB: 2Y00 [23]), SMO (PDB: 4N4W [19]), mGlu1 (PDB: 4OR2 [32]), CRF1 (PDB: 4Z9G [31]), mGlu5 (PDB: 5CGD [34]).”
Structure-Function of the G-protein-Coupled Receptor Superfamily (2012, background): “Several potential allosteric sites in GPCRs revealed by crystal structures have been reviewed previously (53), including a phosphate ion binding site in the extracellular subpocket of the histamine H1 structure (28), a cholesterol binding site in β2AR (40) and a ‘druggable’ extracellular extension o”
Lifting the lid on GPCRs: the role of extracellular loops (2011, background): “A recent model of the PTH1R, based on unpublished NMR data, suggested that there is a short section of a-helix in the middle of this loop (Thomas et al., 2008).”
Generic GPCR Residue Numbers - Aligning Topology Maps Minding The Gaps (2014, background): “…constriction affects the alignment of aminergic receptor binding site residues The TM4 of the aminergic histamine H 1 receptor crystal structure [64] is constricted, directing W158 4.56x57 (an important residue for H 1 R ligand binding based on mutation studies [65]) towards the aromatic…”
Integrating structural and mutagenesis data to elucidate GPCR ligand binding (2016, background): “Within the largest class, A, the histamine H1 [10] and chemokine CXCR4 [11] receptor ligands display the deepest and most superficial binding, respectively.”
Multiple conformational states in retrospective virtual screening – homology models vs. crystal structures: beta-2 adrenergic receptor case study (2015, neutral): “H1R 3RZE [29] 3.”
Modelling dynamics in protein crystal structures by ensemble refinement (2012, neutral): “…3GWH ( Rodríguez et al., 2009 ), 1BV1 ( Gajhede et al., 1996 ), 1IEP ( Nagar et al., 2002 ), 2XFA ( Singh et al., 2011 ), 3ODU ( Wu et al., 2010 ), 1M52 ( Nagar et al., 2002 ), 3CM8 ( He et al., 2008 ) and 3RZE ( Shimamura et al., 2011 TLS-derived B -factor (the parameter p TLS described the…”
Ligand–receptor interaction platforms and their applications for drug discovery (2012, background): “These include rhodopsin [124], b2-adrenergic receptor [125], b1-adrenergic receptor [126], adenosine A2A receptor [127], CXCR4 chemokine receptor [128], dopamine D3 receptor [129], histamine H1 receptor [130], sphingosine 1-phosphate S1P1 receptor [131], muscarinic M3 acetylcholine receptor [132], m”